Bradley McGregor
Clinical Director at Lank Center for Genitourinary Oncology / Instructor in Medicine at Harvard Medical School
Biography
Harvard Medical School
Dr. Bradley A. McGregor is the Clinical Director for the Lank Center of Genitourinary Oncology serving as a Medical Oncologist specializing in genitourinary malignancies at the Dana-Farber Cancer Institute. Completing is undergraduate and medical school education at Tufts University; he then joined the United States Air Force at the San Antonio Uniformed Services Health Education Consortium. While in the military, he completed his post-graduate training in internal medicine, medical oncology and hematology. While in the uniformed services, he provided oncologic care to active duty members, their family members and retirees across the spectrum of benign hematology and medical oncology in San Antonio, TX and northern California at Travis Air Force Base. He served in a multitude of roles including scientific member of the IRB, faculty for the Uniformed Services University of Health Sciences, clinical director and as the program director for the Transitional Year program. In addition, he served in Afghanistan as the Deputy Commander for the NATO led Medical Training Advisory Group where he mentored the Afghan physicians. Reaching the rank of Lieutenant Colonel and receiving the Meritorious Service medal, Dr. McGregor left the Air Force in July of 2016 and came to Dana-Farber. He is actively involved in clinical research in GU malignancies serving as primary investigator for several ongoing trials.
Videos
Dr. McGregor on Future Research in mCRPC
MOA and Management of Any Adverse Effects of Cabozantinib
Dr. McGregor on Combination Therapies With Nivolumab, Cabozantinib, and Sunitinib in RCC
Dr. McGregor on Treating Genitourinary Cancer | Dana-Farber Cancer Institute
Bradley McGregor, MD, describes if biomarkers help guide treatment in advanced renal cell carcinoma
Dr. McGregor on Challenges Facing Frontline Treatments for RCC
Dr. McGregor on Choosing a Combination Therapy Regimen in Advanced RCC
Bradley McGregor, MD, on the data regarding enfortumab in post-platinum + I-O bladder cancer
Bradley McGregor, MD, considers the optimal approach to treating newly diagnosed RCC patients
Bradley McGregor, MD, considers strategies for treating 2nd line RCC patients
Dr. McGregor on Immunotherapy Combinations in Kidney Cancer
Bradley McGregor, MD, on combo ipilimumab + nivolumab in variant histologies of bladder cancer
Bradley McGregor, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in RCC patients
Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers
Dr. McGregor on Whether Patients Need Frontline Combinations in RCC
Read about executive education
Other experts
Popular Courses
Private Equity: Investing and Creating Value
The Wharton School
Philadelphia, Pennsylvania, United States
Sep 8
Leading People and Teams
ESMT
Berlin, Germany
Nov 19
The Manchester Leadership Development Programme
Alliance Manchester Business School
Manchester, United Kingdom
Jul 1
The Positive Leader: Deep Change and Organizational Transformation
Stephen M. Ross School of Business
Ann Arbor, Michigan, United States
Sep 29
Looking for an expert?
Contact us and we'll find the best option for you.